Janus kinase inhibitor cycling may be more effective than switching to bDMARDs among patients with RA who had an inadequate response to initial JAK inhibitor therapy.
Filgotinib maintained a favorable safety and efficacy profile for up to 8 years among patients with RA who participated in the DARWIN 3 LTE.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback